Clinical Characteristics of DKA in Patients with COVID-19 Infection: A Case Series
Shahrokh Sadeghi Boogar
Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Faezeh Sehatpour *
Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Samin Ranjbar
Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Reza Kasaee
Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences. Shiraz, Iran.
Sareh Mosleh-Shirazi
Department of Materials Science and Engineering, Shiraz University of Technology, Shiraz, Iran.
Farnaz Kamali Haghigh Shirazi
Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Rozita Sahraeyan
Shiraz Obstetrics and Gynecology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
*Author to whom correspondence should be addressed.
Abstract
Backgrounds: Diabetes mellitus (DM) is one of the co-morbidities that can increase the mortality rate of COVID-19 patients. The characteristics of patients who present with diabetic ketoacidosis (DKA) and COVID-19 co-morbidity have not been reviewed sufficiently.
Objectives: To investigate the characteristics and outcome of DKA in patients with COVID19 infection.
Methods: In this study, we describe 7 patients admitted to our department with impressions of DKA and concomitant COVID-19. Patients’ lab data, imaging and outcomes were documented in full detail.
Results: The Average of initial random blood sugar and serum HCO3 was 463.71mg/dl and 9.47mmol/L, respectively, among the patients in this survey. The majority of the patients (71%) were presented with DKA symptoms rather than respiratory symptoms related to COVID-19. Four patients expired in this survey. Of the four patients who were expired, all of them presented with moderate DKA, one of them had mild lung involvement, one moderate and two were in a severe category. The average of C-reactive protein (CRP) and Lactate dehydrogenase (LDH) were >150 mg/dl and 813 U/L in the patients who expired respectively.
Conclusion: DKA is a common presentation following an infectious etiology in COVID-19 co morbidity. It can presented with atypical symptoms and divergent outcomes. we suggest that more advances studies with a larger sample size is needed to investigate detailed DKA characteristics, management and outcomes to revise the management protocol of DKA in COVID-19 infection.
Keywords: Diabetic ketoacidosis, COVID-19
How to Cite
Downloads
References
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism. 2020;318(5):E736-E741.
Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1463-1465.
Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis, PloS one. 2020;15(8):e0238215.
Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Research and Clinical Practice. 2020;162.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):303-310.
Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia–a systematic review, meta-analysis, and meta-regression, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):395-403.
McGurnaghan S, Weir A, Bishop J, Kennedy S, Blackbourn L, McAllister D, Hutchinson S, Caparrotta T, Mellor J, Jeyam A. Public health scotland COVID-19 health protection study group; scottish diabetes research network epidemiology group, risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2020;30405-8.
Al Hayek AA, Robert AA, Alotaibi ZK, Al Dawish M. Clinical characteristics of hospitalized and home isolated COVID-19 patients with type 1 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):1841-1845.
Kuchay MS, Reddy PK, Gagneja S, Mathew A, Mishra SK. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):2039-2041.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41(10):2127-2135.
Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. International Journal of Obesity. 2013;37(3):333-340.
Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution, Frontiers in Immunology. 2019;10:1071.
Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):1563-1569.
Armeni E, Aziz U, Qamar S, Nasir S, Nethaji C, Negus R, Murch N, Beynon HC, Bouloux P, Rosenthal M. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. The Lancet Diabetes & Endocrinology. 2020;8(8):660-663.
Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19: Advice from China. Journal of Diabetes. 2020;12(5):417-419.
Palermo NE, Sadhu AR, McDonnell ME. Diabetic ketoacidosis in COVID-19: unique concerns and considerations. The Journal of Clinical Endocrinology & Metabolism. 2020;105(8):2819-2829.
Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, Panebianco V, Andreoli C, Colaiacomo MC, Zingaropoli MA, Ciardi MR. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. European radiology. 2020 Dec;30(12):6808-17.
Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(12):2739-2748.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):535-545.
Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabolism. 2020;31(6):1068-1077. e3.
Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: a report of two cases and review of literature, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1459-1462.
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetologica. 2010;47(3):193-199.
Hollstein T, Schulte DM, Schulz J, Glück A, Ziegler AG, Bonifacio E, Wendorff M, Franke A, Schreiber S, Bornstein SR. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nature Metabolism. 2020;2(10):1021-1024.
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, M.E. Cooper, Z. Chai, New-onset diabetes in Covid-19, New England Journal of Medicine. 2020;383(8):789-790.
Wilcox G. Insulin and insulin resistance. Clinical Biochemist Reviews. 2005;26(2):19.
Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, DeFronzo RA, Cusi K. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005;54(6):1640-1648.
Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhäusl W, Shulman GI. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes. 2000;49(5):701-707.
Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA. Covid-19 and diabetes: A complex bidirectional relationship. Frontiers in Endocrinology. 2020;11:758.
Coate KC, Cha J, Shrestha S, Wang W, Gonçalves LM, Almaça J, Kapp ME, Fasolino M, Morgan A, Dai C. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metabolism. 2020;32(6):1028-1040. e4.
Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes, Obesity and Metabolism. 2020;22(10):1935-1941.
Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M, Lu Y. COVID-19 treatment: close to a cure?–a rapid review of pharmacotherapies for the novel coronavirus. International Journal of Antimicrobial Agents. 2020;106080.
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress, Diabetes Research and Clinical Practice. 2020;108142.
Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers, AIDS (London, England). 2007;21(16):2183.
Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, Yu Z, Zhang W, Zhong Q, Zheng X. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Annals of Intensive Care. 2020;10(1): 1- 24.
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, Voigt D, Courtney H, Atkins H, Platts J. Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic, Diabetic Medicine. 2020;37(7):1214-1216.